St. Jude Medical upgraded at RBC Capital As noted earlier, RBC Capital upgraded St. Jude Medical to Sector Perform from Underperform. After conducting a survey, the firm does not expect concerns about the durability of the company's Durata lead to significantly impact the company's results in 2014. Target to $64 from $44.
Leerink medical devices analyst holds an analyst/industry conference call Medical Devices Analyst Antalffy discusses the ultimate market opportunity for leadless pacers and compares Medtronic vs St. Jude Medical on an Analyst/Industry conference call to be held on September 24 at 2 pm.
St. Jude Medical recent weakness a buying opportunity, says Barclays Barclays said St. Jude Medical weakness is a buying opportunity. The analyst said CardioMEMS is underappreciated by the Street and valuation compelling given sequential revenue growth. Shares are Overweight rated.